Condition: Aneurysm Cerebral · Bifurcation · Unruptured Intracranial Aneurysm · Sponsor: LuSeed Vascular LTD.
The primary objective of this clinical investigation is to evaluate the early safety and feasibility of the LuSeed Aneurysm Embolization System for treating unruptured intracranial aneurysms (IA). This is a prospective, single-arm, open-label, multi-center, interventional study, screening patients approved for treatment of unruptured IAs based on national or international guidelines. Up to 30 eligible subjects meeting inclusion and exclusion criteria and providing consent will be enrolled across a maximum of 10 medical centers in the EU.
This description comes directly from the study's public registry record.
Nitzan Hirsh · 972-545333200 · Nitzan.h@luseed-vascular.com
Gali Vino · 972525527565 · galiv@luseed-vascular.com
Always discuss trial participation with your own doctor first.
| University Hospital St. Ivan Rilski | Sofia, Bulgaria | Recruiting |
| The University Medical Center Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| Sheba Medical Center | Tel Litwinsky, Israel | Recruiting |
| UCK Katowice | Katowice, Poland | Recruiting |
| Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz | Lodz, Poland | Recruiting |
| Jan Mikulicz-Radecki University Clinical Hospital in Wrocław | Wroclaw, Poland | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06761365